Compugen Ltd. (CGEN) Stock Price & How to Invest

Last updated November 2026

Short answer

Compugen (CGEN) is an Israeli computational drug-discovery biotech that closed at ~$1.84 on November 20, 2026, a market value of roughly ~$174 million against ~$117.5 million of cash and almost no debt. Owning it is mostly a bet on three things: royalties from AstraZeneca's rilvegostomig, milestones from Gilead's GS-0321, and the COM701 ovarian cancer readout due by the end of Q1 2027. Revenue is lumpy and partner-driven, not product sales.

CGEN stock price

As of 2026-11-20, Compugen Ltd. (CGEN) last closed at $1.84, up 20.3% over the past year. Over the past 52 weeks it has traded between $1.47 and $3.10.

CGEN last close
$1.84
1 day
-2.13%
1 month
-13.21%
1 year
+20.26%
52-week range
$1.47 to $3.10
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Compugen Ltd.'s investor relations page. Walnut is informational, not investment advice.

CGEN key stats

At $1.84 on November 20, 2026, Compugen Ltd. (CGEN) has a market cap of $174M and a P/E of 4.7 on trailing earnings.

Market cap
$174M
P/E (trailing)
4.7
EPS (trailing 12 months)
$0.39
Price to book
2.1
Beta
2.82

Market cap, P/E and yield are measured at the $1.84 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Compugen Ltd. (CGEN)?

The last two weeks for Compugen Ltd., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • CGEN closed at $1.84 on November 20, 2026, down 12.4% over the past five trading days (from $2.10).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Compugen Ltd. (CGEN) do?

Compugen Ltd. is a clinical-stage immuno-oncology company based in Holon, Israel, listed on Nasdaq and the Tel Aviv Stock Exchange. Its edge has always been computational: a predictive discovery platform used to find new drug targets in the immune system. That platform produced the antibodies behind its pipeline. COM701 is a first-in-class antibody against PVRIG, which Compugen develops itself. COM902, an anti-TIGIT antibody, is the source of the TIGIT arm of rilvegostomig, the PD-1/TIGIT bispecific that AstraZeneca licensed and now runs in about 12 Phase 3 trials. GS-0321 (formerly COM503), an antibody that blocks IL-18 binding protein, was licensed to Gilead in late 2024 and is in Phase 1 dose escalation.

The financials read strangely because almost all revenue comes from partners. In 2025 Compugen reported ~$72.8 million of revenue and ~$35.3 million of net profit, but that was driven by a one-time $65 million payment from AstraZeneca in December 2025 for a slice of future rilvegostomig royalties, with up to $25 million more on BLA acceptance. Strip that out and the run rate is small. Q3 2026, reported November 9, brought revenue of ~$3.8 million, about double the ~$1.9 million of a year earlier and above estimates, from recognized Gilead payments; R&D was ~$5.8 million, G&A ~$2.3 million and the net loss ~$5.8 million, or $0.06 per share, better than the ~$0.09 consensus. Cash, deposits and securities were ~$117.5 million at September 30, 2026, down from ~$145.6 million at year end, with no meaningful debt and management still guiding to a runway into 2029.

The investment picture is a sum of parts trading at a discount. At ~$1.84 and ~94.6 million shares, the equity is worth ~$174 million, so the market assigns roughly ~$57 million to everything beyond the cash pile. That modest number reflects history: several big-pharma TIGIT programs were dropped after disappointing trials, which colors how investors view rilvegostomig. The near-term swing factor is COM701's MAIA-ovarian trial, a randomized, placebo-controlled maintenance study in relapsed platinum-sensitive ovarian cancer that is now fully enrolled with 62 patients randomized 2:1, with results guided by the end of Q1 2027. For rilvegostomig, AstraZeneca's first Phase 3 readout, ARTEMIDE-Biliary01 in 760 biliary tract cancer patients, is now expected in the second half of 2027. The shares closed at ~$1.84 on November 20, 2026, up ~19% year to date and ~21% over one year but down ~36% over three months, which suggests patience is wearing thin ahead of those readouts.

What's driving Compugen Ltd. (CGEN)?

1. Rilvegostomig royalties at AstraZeneca

The largest long-term value driver is a drug Compugen does not run. AstraZeneca's rilvegostomig combines PD-1 blockade with a TIGIT arm derived from Compugen's COM902, and AstraZeneca has expanded it into about 12 Phase 3 trials across lung, biliary tract, gastric, urothelial and other cancers, including a newly started combination with Datroway in urothelial cancer. At ASCO 2026, the GEMINI-Hepatobiliary study showed a ~16.8 month median overall survival in first-line biliary tract cancer, the drug's first OS readout. Compugen keeps the majority of its tiered royalties (up to mid-single digits) after the December 2025 sale, plus remaining milestones and a potential ~$25 million payment on BLA acceptance. AstraZeneca reported Phase 2 ARTEMIDE-01 overall survival data in September 2026 that compared favorably with historical controls, and the first Phase 3 result, ARTEMIDE-Biliary01 in 760 biliary tract cancer patients, is now expected in the second half of 2027. Compugen is eligible for up to ~$195 million in additional milestones, with most Phase 3 readouts coming in 2027 and later.

2. COM701 and the MAIA-ovarian readout

COM701 is Compugen's wholly owned, first-in-class anti-PVRIG antibody, and MAIA-ovarian is the company's most important in-house test. The trial evaluates COM701 as a maintenance monotherapy in second- and third-line relapsed platinum-sensitive ovarian cancer, a setting where patients often have limited options once PARP inhibitors are used up. The design is randomized and placebo-controlled, which makes the result cleaner than the single-arm data that earlier PVRIG work relied on. Enrollment is complete, with 62 patients randomized 2:1 to COM701 or placebo across sites in the U.S., Israel and France, and management guides to results by the end of Q1 2027. A small trial gives a fast answer but leaves room for noise. A clear signal could support partnering talks; a miss would leave Compugen mainly a royalty holder.

3. Gilead and GS-0321 milestones

In December 2024 Gilead licensed COM503, now GS-0321, an antibody designed to block IL-18 binding protein so that the immune system's own IL-18 can act inside tumors. Compugen received a ~$60 million upfront payment and a ~$30 million milestone when the IND cleared in 2025, and it is eligible for up to roughly ~$758 million in further development, regulatory and commercial milestones, plus tiered royalties. The Phase 1 dose-escalation study is progressing under Gilead's control. Compugen still recognizes portions of those earlier payments as revenue, which is why quarterly revenue runs at ~$2 million to ~$3 million, and it carried ~$31.8 million of deferred revenue at mid-2026. Q3 2026 revenue of ~$3.8 million came from the same source, and no new milestone was reported in the quarter.

4. Cash runway and a cheap enterprise value

Compugen's balance sheet is unusual for a small biotech. Cash, deposits and marketable securities were ~$117.5 million at September 30, 2026, against a market cap near ~$174 million and minimal debt, leaving an enterprise value of roughly ~$57 million. Quarterly cash burn has been running around ~$7 million to ~$10 million, and management says current funds cover operations into 2029 without any further inflows. That matters because it means the company can reach the MAIA-ovarian results and the first rilvegostomig Phase 3 readout without needing to raise equity at depressed prices. Any new milestone from AstraZeneca or Gilead would extend that runway further. In October 2026 Compugen also introduced UnigenX, an extension of its AI discovery platform aimed at finding tumor-associated antigens for T cell engagers and similar formats, a possible source of future partner deals.

What are the risks to Compugen Ltd. (CGEN)?

The biggest risk is that the TIGIT class does not work well enough. Roche, Merck and others discontinued TIGIT programs after disappointing late-stage results, and if rilvegostomig's Phase 3 trials follow that path, the royalty stream that underpins much of Compugen's value could shrink toward zero. Compugen also has no control over AstraZeneca's or Gilead's priorities, timelines or decisions to cut programs. COM701 is a single binary event: MAIA-ovarian, with only 62 patients, could show no meaningful benefit, and PVRIG has never been validated in a randomized trial. Rilvegostomig's first Phase 3 readout has also moved to the second half of 2027. Revenue is irregular and partner-driven, so headline profit in 2025 says little about the underlying business, which lost ~$5.8 million in Q3 2026 and ~$6 million to ~$8 million in earlier quarters. Having already sold part of its rilvegostomig royalties, Compugen has given up some upside in exchange for cash today. The stock traded at ~$1.84 on November 20, 2026, after a ~36% three-month fall, a level where Nasdaq's $1 minimum bid rule has bitten before (Compugen regained compliance in January 2024 after falling below it). As an Israeli company, it also carries currency and regional geopolitical exposure, and thin trading can make the shares move sharply on small news. Finally, if MAIA-ovarian succeeds, a larger registrational trial would cost far more than today's burn, which could mean dilution or a partnership on less favorable terms.

What is the Compugen Ltd. (CGEN) forecast?

5 analysts publish price targets on CGEN, averaging $4.80 as of November 2026, or +160.9% against the $1.84 share price on November 20, 2026. The published targets run from $4.00 to $6.00, a moderate spread, and the ratings split 5 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CGEN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is CGEN a buy or a sell?

We give no verdict on Compugen Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Rilvegostomig royalties at AstraZeneca. The largest long-term value driver is a drug Compugen does not run. The most optimistic published target, $6.00, assumes this works close to its best case.

The case against. The biggest risk is that the TIGIT class does not work well enough. The most pessimistic target, $4.00, is roughly what CGEN is worth if this bites instead.

Read the full bull and bear case on CGEN, including what would have to change to break either one. Walnut is not an investment adviser.

How is Compugen Ltd. (CGEN) valued?

Market cap, P/E and dividend yield at today's price are in the CGEN key stats above. The business figures below come from Compugen Ltd.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$76 million (incl. ~$65 million one-time royalty sale); Q3 2026 ~$3.8 million
  • Net income (TTM): ~$36 million (one-time driven); Q3 2026 loss ~$5.8 million
  • Cash and investments: ~$117.5 million (September 30, 2026), minimal debt
  • Enterprise value: ~$57 million

As of November 2026: Traditional ratios do not describe Compugen well. The trailing P/E of ~4.7 looks cheap only because trailing revenue and profit include the ~$65 million December 2025 royalty sale to AstraZeneca; the recurring business generates ~$2 million to ~$4 million of revenue a quarter and a loss of ~$6 million to ~$8 million. The more useful lens is enterprise value: at ~$1.84 per share, the market places roughly ~$57 million on the pipeline above cash, about 2.1 times book equity. The five analysts tracked by Yahoo Finance have a mean target near $4.80 with a strong buy consensus, but for a company like this, valuation moves on trial data and partner news, not on quarterly earnings, so the cash balance and the burn rate are the figures that tend to anchor the share price between catalysts.

Who competes with Compugen Ltd. (CGEN)?

TIGIT and PD-1 bispecific developers

Rilvegostomig competes with other drugs that pair PD-1 and TIGIT blockade, including Arcus Biosciences and Gilead's domvanalimab, plus several Chinese bispecifics. Roche's tiragolumab and Merck's vibostolimab were dropped after weak late-stage results, which both clears the field and raises doubts about the whole mechanism Compugen's royalty depends on.

Ovarian cancer maintenance therapies

COM701 targets maintenance in relapsed platinum-sensitive ovarian cancer, where AstraZeneca and Merck's Lynparza and GSK's Zejula (PARP inhibitors) set the standard, and AbbVie's Elahere covers a defined biomarker subset. COM701 has to show benefit in patients who have already moved past these drugs, which is a demanding comparison.

Computational and early immuno-oncology platforms

Compugen's discovery model competes for partner deals with other target-discovery and immuno-oncology biotechs such as Absci, Recursion and other AI-driven antibody developers. Big pharma licenses from many sources, so Compugen has to keep producing novel, validated targets like PVRIG and IL-18BP to win the next Gilead-style deal.

What stocks are similar to Compugen Ltd. (CGEN)?

Other names that sit close to CGEN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Compugen Ltd. (CGEN)

There are three common ways to get CGEN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CGEN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CGEN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Compugen Ltd. (CGEN)

CGEN is a cash-backed option on partner programs plus one binary in-house readout. The market prices the pipeline at only ~$57 million above cash, which reflects real doubt about TIGIT-class drugs and about COM701 ahead of its early-2027 data.

More on Compugen Ltd. (CGEN)

Whether CGEN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CGEN a buy or a sell?, and where the stock could go from here in the CGEN stock forecast.

For income investors, whether CGEN pays a dividend and how the payout looks is covered in does CGEN pay a dividend? And to weigh CGEN against a peer, read the full side-by-side comparisons: CGEN vs PD and CGEN vs RCUS.

Wondering how CGEN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Compugen Ltd.

Ask Walnut's AI anything about CGEN and see how it fits what you own.

FAQ

What does Compugen do?

+

Compugen is a clinical-stage biotech in Holon, Israel, that uses a computational discovery platform to find new immune checkpoint targets and then builds antibodies against them. It has three programs that matter today. COM701, an antibody against PVRIG, is wholly owned and in a randomized ovarian cancer trial. The TIGIT component of AstraZeneca's rilvegostomig came from Compugen's COM902, so Compugen earns milestones and royalties on that drug. GS-0321, an IL-18 binding protein blocker, is licensed to Gilead and in Phase 1. The company has no marketed products, so all of its revenue comes from license, milestone and royalty-related payments from those two partners.

Why did Compugen report a profit in 2025?

+

Compugen reported ~$72.8 million of revenue and ~$35.3 million of net profit for 2025, but nearly all of that came from one transaction. In December 2025 it sold a portion of its future rilvegostomig royalties back to AstraZeneca for $65 million upfront, with up to $25 million more if a BLA is accepted. It also booked a $5 million clinical milestone from AstraZeneca and recognized portions of Gilead payments. Without the royalty sale, the business ran at a loss. In 2026, quarterly revenue fell back to ~$2 million to ~$4 million, and net losses returned, at ~$5.8 million to ~$7.7 million per quarter. The 2025 profit is a one-time event, not a trend.

How much cash does Compugen have?

+

At September 30, 2026, Compugen held ~$117.5 million in cash, cash equivalents, short-term bank deposits and marketable securities, with minimal debt. That was down from ~$125.3 million at June 30 and ~$145.6 million at the end of 2025, the result of roughly ~$8 million to ~$10 million of quarterly burn. Management says that balance funds its operating plans into 2029, assuming no further inflows. Against a market cap near ~$174 million at ~$1.84 per share (November 20, 2026), cash represents about two thirds of the company's equity value, which is why the enterprise value is only around ~$57 million.

What is rilvegostomig and why does it matter to CGEN?

+

Rilvegostomig is AstraZeneca's bispecific antibody that blocks both PD-1 and TIGIT, two brakes on the immune system. Its TIGIT arm is derived from Compugen's COM902, which is why Compugen holds milestone and royalty rights. AstraZeneca has made it a major bet, with about 12 Phase 3 trials across several cancers, and it reported a ~16.8 month median overall survival in first-line biliary tract cancer at ASCO 2026. If it reaches the market, Compugen would collect tiered royalties up to mid-single digits on sales, plus a potential ~$25 million on BLA acceptance. The first Phase 3 result, from the ARTEMIDE-Biliary01 trial in biliary tract cancer, is now expected in the second half of 2027, and Compugen is eligible for up to ~$195 million in further milestones, so this is a long-dated driver.

When is the next big catalyst for Compugen?

+

The most closely watched event is MAIA-ovarian, the randomized, placebo-controlled trial testing COM701 as maintenance therapy in relapsed platinum-sensitive ovarian cancer. It completed enrollment with 62 patients randomized 2:1, and management guides to results by the end of Q1 2027. Because COM701 is wholly owned, a positive result would accrue fully to Compugen and could open partnering discussions, while a negative one would leave the company mostly dependent on partner programs. Other events include the Q4 2026 report, expected in early 2027, AstraZeneca's first rilvegostomig Phase 3 readout in biliary tract cancer in the second half of 2027, and progress in Gilead's GS-0321 Phase 1 study, which could eventually trigger new milestone payments.

Is Compugen stock cheap?

+

By one measure it looks inexpensive: at ~$1.84 a share on November 20, 2026, the ~$174 million market value sits only about ~$57 million above the company's ~$117.5 million of cash, so investors are paying relatively little for the rilvegostomig royalties, the Gilead milestones and COM701 combined. Price to book is around ~2.1 times. That discount exists for reasons, though. TIGIT drugs have a poor track record in late-stage trials, Compugen controls neither partner program, and COM701 faces its first randomized test. Analyst targets remain well above the share price (mean ~$4.80), but Leerink earlier cut its target to $5 from $13. Whether the gap closes depends on clinical data, not on earnings.

What are the main risks of owning CGEN?

+

The central risk is clinical. If AstraZeneca's Phase 3 trials of rilvegostomig disappoint, as several rival TIGIT programs did at Roche and Merck, much of Compugen's long-term royalty value would disappear. COM701 has never been proven in a randomized trial, and the 62-patient MAIA-ovarian trial could show no benefit. Compugen depends on partners whose priorities it cannot control, and it already sold part of its rilvegostomig royalties. The shares trade below $2 with thin volume, so they can swing sharply on news, and the company fell below Nasdaq's $1 minimum bid before regaining compliance in 2024. Israeli geopolitical and currency risks add a further layer.

How does Compugen make money long term?

+

Compugen's model is to discover targets, take some programs into early clinical trials, and license others to large drugmakers in exchange for upfront fees, milestones and royalties. From AstraZeneca it can earn remaining development and regulatory milestones and tiered royalties of up to mid-single digits on rilvegostomig sales. From Gilead it received ~$90 million so far (upfront plus the IND milestone) and is eligible for up to ~$758 million more, plus royalties on GS-0321. COM701 could be partnered or developed further if MAIA-ovarian succeeds. Until any drug is approved, revenue will stay irregular, so the company relies on its cash balance to fund research.

How did Compugen do in its latest quarter?

+

In Q3 2026, reported November 9, Compugen's revenue roughly doubled to ~$3.8 million from ~$1.9 million a year earlier, beating estimates, as it recognized more of Gilead's earlier payments. R&D held at ~$5.8 million and G&A was ~$2.3 million, so the net loss narrowed to ~$5.8 million, or $0.06 per share, against a consensus loss of ~$0.09. Cash was ~$117.5 million with runway guided into 2029. The bigger news was operational: MAIA-ovarian completed enrollment, and AstraZeneca's first rilvegostomig Phase 3 readout moved to the second half of 2027.

How has CGEN stock performed in 2026?

+

As of November 20, 2026, Compugen closed at ~$1.84, up about 19% year to date and about 21% over one year. The recent trend is weaker: the shares fell about 36% over three months, from levels above $2.40 in August, and sit inside a 52-week range of ~$1.43 to ~$3.24. Moves of this size are common for a small biotech waiting on binary trial data. Walnut is not an investment adviser.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Compugen Ltd.'s investor relations page or your broker before making investment decisions.